With over three decades of extensive industry experience, Ramesh Juneja brings a strong track record of building and scaling large businesses
A one-shot gene-editing cholesterol therapy could soon be a reality
The decision clears the drug as a monotherapy for adults with unresectable, locally advanced or metastatic non-small cell lung cancer
The company is expected to conduct further studies to confirm the long-term efficacy and safety of Vijoice in both adult and paediatric patients
AAV vectors are widely used in gene therapy for their strong therapeutic potential
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
Revenue from operations climbed 13% to Rs. 886.87 crore
Subscribe To Our Newsletter & Stay Updated
